Antiviral immunotropic agent for the treatment of acute respiratory viral infections

Inventors

CHERTORIZHSKY, Evgeny Alexandrovich • Ovchinnikov, Mikhail Vladimirovich • Kleimenov, Aleksey Viktorovich

Assignees

PVP Labs Pte Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11365216-B2

Patent

Publication Date

2022-06-21

Expiration Date


Abstract

The proposed methods of treatment pertain to medicine, in particular pharmacology, and concerns the application of a nasal medicinal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral infections (ARVIs), in particular those caused by the influenza virus.

Core Innovation

The disclosed method concerns intranasal administration of a nasal medicinal composition containing the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine, or a pharmaceutically acceptable salt, to stimulate phagocytosis by neutrophils and macrophages and production of endogenous interferons during treatment of acute respiratory viral diseases. The supplied summary also describes direct antiviral and immunomodulating effects, including use in relation to influenza.

The reported preclinical findings include inhibition of influenza virus and suppression of adenovirus cytopathic effects, alongside increased interferon-α production, phagocytic activity, and natural-killer-cell cytotoxicity. The summary also reports improved survival in influenza-infected mice and reduced pro-inflammatory cytokine production. The partial content does not provide the background section; therefore, the problem identified in that section is not explicitly described in patent.

Claims Coverage

The provided claims identify one independent claim featuring one inventive feature.

Intranasal stimulation of phagocytosis and endogenous interferon production

The independent claim covers intranasally administering a nasal medicinal composition comprising the specified hexapeptide or a pharmaceutically acceptable salt to stimulate phagocytosis of neutrophils and macrophages and production of endogenous interferons during treatment of acute respiratory viral diseases.

The independent claim centers on the intranasal use of the specified hexapeptide or its pharmaceutically acceptable salt to stimulate phagocytosis and endogenous interferon production during treatment of acute respiratory viral diseases.

Stated Advantages

The summary reports direct antiviral and immunomodulating effects, including inhibition of influenza virus and suppression of adenovirus cytopathic effects.

The reported preclinical findings include improved survival in influenza-infected mice, increased interferon-α production and phagocytic activity, enhanced natural-killer-cell cytotoxicity, and reduced pro-inflammatory cytokine production.

Documented Applications

Intranasal treatment of acute respiratory viral diseases, including influenza.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.